JP2006517670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517670A5 JP2006517670A5 JP2006503224A JP2006503224A JP2006517670A5 JP 2006517670 A5 JP2006517670 A5 JP 2006517670A5 JP 2006503224 A JP2006503224 A JP 2006503224A JP 2006503224 A JP2006503224 A JP 2006503224A JP 2006517670 A5 JP2006517670 A5 JP 2006517670A5
- Authority
- JP
- Japan
- Prior art keywords
- marinobufagenin
- normal range
- significant increase
- eclampsia
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FRYICJTUIXEEGK-UHFFFAOYSA-N 5beta-hydroxyldesacetylcinobufagin Natural products CC12CCC(C3(CCC(O)CC3(O)CC3)C)C3C11OC1C(O)C2C=1C=CC(=O)OC=1 FRYICJTUIXEEGK-UHFFFAOYSA-N 0.000 claims 30
- JMNQTHQLNRILMH-OBBGIPBRSA-N marinobufagenin Chemical compound C=1([C@H]2C[C@H]3O[C@@]43[C@H]3[C@@H]([C@]5(CC[C@H](O)C[C@@]5(O)CC3)C)CC[C@@]42C)C=CC(=O)OC=1 JMNQTHQLNRILMH-OBBGIPBRSA-N 0.000 claims 30
- 238000000034 method Methods 0.000 claims 10
- 201000011461 pre-eclampsia Diseases 0.000 claims 10
- 239000000523 sample Substances 0.000 claims 4
- 210000002700 urine Anatomy 0.000 claims 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 claims 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 229940095074 cyclic amp Drugs 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44473003P | 2003-02-04 | 2003-02-04 | |
| PCT/US2004/002802 WO2004071273A2 (en) | 2003-02-04 | 2004-02-02 | Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006517670A JP2006517670A (ja) | 2006-07-27 |
| JP2006517670A5 true JP2006517670A5 (https=) | 2007-04-05 |
| JP4625800B2 JP4625800B2 (ja) | 2011-02-02 |
Family
ID=32869296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503224A Expired - Fee Related JP4625800B2 (ja) | 2003-02-04 | 2004-02-02 | マリノブファゲニンの増加を利用して子癇前症の有無を判定する方法及び関連装置 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7439071B2 (https=) |
| EP (1) | EP1592967A4 (https=) |
| JP (1) | JP4625800B2 (https=) |
| AU (1) | AU2004210650C1 (https=) |
| BR (1) | BRPI0407213A (https=) |
| CA (1) | CA2515012A1 (https=) |
| WO (1) | WO2004071273A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7794716B2 (en) | 2002-07-25 | 2010-09-14 | Glenveigh Pharmaceuticals, Llc | Antibody composition and passive immunization against pregnancy-induced hypertension |
| US7402313B2 (en) | 2002-07-25 | 2008-07-22 | Charles David Adair | Method for controlling preeclampsia and eclampsia |
| ATE537823T1 (de) * | 2004-10-19 | 2012-01-15 | Univ Tulane | Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin |
| US8038997B2 (en) | 2005-06-27 | 2011-10-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-marinobufagenin antibodies and methods for their use |
| US20070257366A1 (en) * | 2006-05-03 | 2007-11-08 | Taiwan Semiconductor Manufacturing Company, Ltd. | Barrier layer for semiconductor interconnect structure |
| US20080299602A1 (en) * | 2007-05-31 | 2008-12-04 | Puschett Jules B | Methods of Employing Vascular Leakage to Diagnose a Capillary Leak Disorder |
| WO2010104646A1 (en) * | 2009-03-09 | 2010-09-16 | Scott and White Memorial Hospital | Method of testing a patient for hypertension and related method of treatment and test kit |
| US20110008904A1 (en) * | 2009-07-10 | 2011-01-13 | Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation | Method for determining if a patient has a traumatic brain injury and related apparatus |
| US20110207154A1 (en) * | 2010-01-12 | 2011-08-25 | Scott & White Healthcare | Method for determination of marinobufagenin levels and compounds employable in such method |
| US20160299130A1 (en) * | 2015-04-09 | 2016-10-13 | Jules B. Puschett | Telocinobufagin (TCINO) in the Diagnosis and Pathogenesis of Preeclampsia, Traumatic Brain Injury and Acute Respiratory Distress Syndrome |
| EP3813879A1 (en) | 2018-06-21 | 2021-05-05 | CTS Biopharma LLC | Anti-marinobufagenin antibodies and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5079171A (en) * | 1988-09-15 | 1992-01-07 | Adeza Biomedical Corporation | Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin |
| WO1990007122A1 (en) * | 1988-12-14 | 1990-06-28 | The Regents Of The University Of California | Diagnostic assay for the detection of preeclampsia |
| GB9213934D0 (en) * | 1992-06-30 | 1992-08-12 | Smithkline Beecham Corp | Chemical compounds |
| US5770376A (en) * | 1992-12-02 | 1998-06-23 | Biomedical Sciences Research Laboratories, Inc. | Method of diagnosing and treating myocardial infarction and hypertension |
| WO1994012210A1 (en) | 1992-12-02 | 1994-06-09 | Bagrov Alexei Y | Anti-edlf antibody, composition thereof and method of diagnosing and treating cardiac arrhythmias, hypertension |
| US5543138A (en) * | 1994-03-10 | 1996-08-06 | Genetics Institute, Inc. | Methods of diagnosing and treating preeclampsia |
| GB9618931D0 (en) * | 1996-09-11 | 1996-10-23 | Univ London | Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes |
| US20030044856A1 (en) * | 1997-09-26 | 2003-03-06 | Puschett Jules B. | Method of determining volume dependent hypertension through protein reduction in phosphorylation or concentration and related apparatus |
| JPH11271222A (ja) * | 1998-03-24 | 1999-10-05 | Sekisui Chem Co Ltd | 尿検査方法 |
| US7794716B2 (en) * | 2002-07-25 | 2010-09-14 | Glenveigh Pharmaceuticals, Llc | Antibody composition and passive immunization against pregnancy-induced hypertension |
| US10167609B1 (en) | 2018-01-12 | 2019-01-01 | Cashman Dredging & Marine Contracting Co., LLC | Carouseling articulated dredge and barge |
-
2004
- 2004-02-02 CA CA002515012A patent/CA2515012A1/en not_active Abandoned
- 2004-02-02 AU AU2004210650A patent/AU2004210650C1/en not_active Ceased
- 2004-02-02 EP EP04707392A patent/EP1592967A4/en not_active Withdrawn
- 2004-02-02 JP JP2006503224A patent/JP4625800B2/ja not_active Expired - Fee Related
- 2004-02-02 BR BR0407213-8A patent/BRPI0407213A/pt not_active IP Right Cessation
- 2004-02-02 US US10/544,468 patent/US7439071B2/en not_active Expired - Fee Related
- 2004-02-02 WO PCT/US2004/002802 patent/WO2004071273A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bajaj et al. | Autologous serum therapy in chronic urticaria: Old wine in a new bottle | |
| RU2008127252A (ru) | Эффекты ингибиторов fgfr3 на транскрипцию генов | |
| RU2020122011A (ru) | Способ определения концентрации в растворе | |
| JP2006517670A5 (https=) | ||
| JP2014521308A5 (https=) | ||
| DE60326214D1 (de) | Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten | |
| RU2012147597A (ru) | Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания | |
| JP2020521794A5 (https=) | ||
| WO2007092427A3 (en) | Treatment of endotoxemia using endotoxin neutralizing agents | |
| ATE529743T1 (de) | Verfahren und kits zur tumorigenizitätsdiagnose | |
| RU2008116567A (ru) | Биомаркеры | |
| UA99094C2 (ru) | Способ лечения пациента с системной красной волчанкой | |
| EP1162457A3 (en) | Multiple coagulation test system and method of using a multiple coagulation test system | |
| RU2009106718A (ru) | Применение белка с меланома-ингибирующей активностью (миа) в качестве раннего индикатора терапевтического ответа при меланоме | |
| Alsulami Sr et al. | Early versus late initiation of hydrocortisone in patients with septic shock: a prospective study | |
| Hatta et al. | Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients | |
| WO2003011215A3 (en) | Method and system to determine revised dosage | |
| BRPI0407213A (pt) | Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados | |
| Stojanovic et al. | The impact of malnutrition on mortality in patients on maintenance hemodialysis in Serbia | |
| Gallagher et al. | Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials | |
| Helwig et al. | Proposal for an anti-TNF-exit strategy based on trough serum level | |
| Reed et al. | 70. Cortisol Response to Psychosocial Stress and Working Memory Performance in Schizophrenia | |
| EA201300410A1 (ru) | Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2 | |
| Lin et al. | Tissue destruction induced by Porphyromonas gingivalis infection in a mouse chamber model is associated with host tumor necrosis factor generation | |
| ATE537823T1 (de) | Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin |